Search results
Argenx stock gets H.C. Wainwright nod on Vyvgart growth and pipeline progress By Investing.com
Investing.com· 1 day agoThe firm's confidence in argenx is rooted in the company's successful introduction of Vyvgart for...
Dianthus receives FDA greenlight to begin Phase II trial in MMN
Clinical Trials Arena via Yahoo Finance· 3 days agoDianthus says DNTH103 “holds the potential to be a pipeline in a product”, citing potential...
Lichen Planopilaris: Prevalence, Treatments in the US
Medscape· 4 days agoMost patients diagnosed with LPP received at least one type of medication, most commonly...
Solving RLS: Largest Genetic Study to Date May Help
Medscape· 2 days agoFor decades, scientists have been trying to unravel the mysteries of restless legs syndrome (RLS), a poorly understood and underdiagnosed neurological...
Kyverna Therapeutics’ CAR-T cell therapy shows promise against autoimmune diseases
BioPharma-Reporter· 5 days agoKYV-101 has shown promising results in treating 12 different autoimmune conditions, including systemic lupus erythematosus (SLE) and myasthenia gravis ( ...
FDA clears Dianthus Therapeutics' Phase 2 MMN drug trial By Investing.com
Investing.com· 3 days agoDianthus Therapeutics, Inc. (NASDAQ:DNTH), a biotech firm, has received FDA clearance for a Phase 2...
argenx’s (ARGX) “Buy” Rating Reaffirmed at HC Wainwright
ETF DAILY NEWS· 2 days agoHC Wainwright’s price objective would suggest a potential upside of 15.36% from the stock’s current price. Other research analysts have also issued research reports about the company. JMP Securities ...
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Oppenheimer
ETF DAILY NEWS· 14 hours agoOppenheimer restated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $50.00 price ...
Cabaletta Bio (NASDAQ:CABA) Shares Gap Up to $12.56
ETF DAILY NEWS· 1 day agoCabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $12.56, but opened at $13.35. Cabaletta Bio shares last ...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Forecasted to Post Q2 2024 Earnings of ($0.58) Per Share
ETF DAILY NEWS· 3 days agoDianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Equities researchers at Lifesci Capital...